These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials. EFSA GMO Panel Working Group on Animal Feeding Trials Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408 [TBL] [Abstract][Full Text] [Related]
3. Perspectives of monoclonal antibodies for detection and treatment of head and neck tumours. Quak J; Gerretsen M; De Bree R; Brakenhof R; Van Dongen G; Snow G Anticancer Res; 1993; 13(6B):2533-9. PubMed ID: 8135493 [TBL] [Abstract][Full Text] [Related]
5. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803 [TBL] [Abstract][Full Text] [Related]
6. Antibodies in oncology. Pillay V; Gan HK; Scott AM N Biotechnol; 2011 Sep; 28(5):518-29. PubMed ID: 21473941 [TBL] [Abstract][Full Text] [Related]
7. Hazard identification and risk assessment for biologics targeting the immune system. Weir AB J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852 [TBL] [Abstract][Full Text] [Related]
8. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic. Arnett HA; Viney JL Adv Drug Deliv Rev; 2007 Sep; 59(11):1084-92. PubMed ID: 17804112 [TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems. Dixit R; Coats S IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884 [TBL] [Abstract][Full Text] [Related]
10. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Khawli LA; Hu P; Epstein AL Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies for cancer therapy. Catane R; Longo DL Isr J Med Sci; 1988; 24(9-10):471-6. PubMed ID: 3060441 [TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
13. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759 [TBL] [Abstract][Full Text] [Related]
15. Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis. Okamoto OK; Perez JF Expert Rev Mol Diagn; 2008 Jul; 8(4):387-93. PubMed ID: 18598221 [TBL] [Abstract][Full Text] [Related]
17. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Beckman RA; Weiner LM; Davis HM Cancer; 2007 Jan; 109(2):170-9. PubMed ID: 17154393 [TBL] [Abstract][Full Text] [Related]
18. Animal studies in the development of medical countermeasures. Roberts R; McCune SK Clin Pharmacol Ther; 2008 Jun; 83(6):918-20. PubMed ID: 18323860 [TBL] [Abstract][Full Text] [Related]
19. Development and regulation of monoclonal antibody products: challenges and opportunities. Weinberg WC; Frazier-Jessen MR; Wu WJ; Weir A; Hartsough M; Keegan P; Fuchs C Cancer Metastasis Rev; 2005 Dec; 24(4):569-84. PubMed ID: 16408162 [TBL] [Abstract][Full Text] [Related]